ATE495761T1 - Optimierung der behandlung philadelphia-positiver leukämie mit abl-tyrosinkinasehemmer imatinib - Google Patents

Optimierung der behandlung philadelphia-positiver leukämie mit abl-tyrosinkinasehemmer imatinib

Info

Publication number: ATE495761T1
Authority: AT; Austria
Prior art keywords: leukemia; cmin; bcr; tyrosine kinase; philadelphia
Prior art date: 2006-09-22

Application number

AT07842842T

Other languages

English (en)

Inventor

Insa Gathmann

Francois-Xavier Mahon

Mathieu Molimard

Stephane Picard

Yanfeng Wang

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-22

Filing date

2007-09-20

Publication date

2011-02-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE495761(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-09-20 Application filed by Novartis Ag filed Critical Novartis Ag

2011-02-15 Application granted granted Critical

2011-02-15 Publication of ATE495761T1 publication Critical patent/ATE495761T1/de

Links

208000032839 leukemia Diseases 0.000 title abstract 4
239000005517 L01XE01 - Imatinib Substances 0.000 title abstract 2
229960002411 imatinib Drugs 0.000 title abstract 2
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 abstract 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
102000004441 bcr-abl Fusion Proteins Human genes 0.000 abstract 1
108010056708 bcr-abl Fusion Proteins Proteins 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
239000002207 metabolite Substances 0.000 abstract 1
210000004214 philadelphia chromosome Anatomy 0.000 abstract 1
230000036470 plasma concentration Effects 0.000 abstract 1
230000035945 sensitivity Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Pathology (AREA)
Ecology (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Immunology (AREA)
Biophysics (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT07842842T 2006-09-22 2007-09-20 Optimierung der behandlung philadelphia-positiver leukämie mit abl-tyrosinkinasehemmer imatinib ATE495761T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US82662206P	2006-09-22	2006-09-22
US82827806P	2006-10-05	2006-10-05
PCT/US2007/078978 WO2008036792A2 (en)	2006-09-22	2007-09-20	Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors

Publications (1)

Publication Number	Publication Date
ATE495761T1 true ATE495761T1 (de)	2011-02-15

Family

ID=39092883

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07842842T ATE495761T1 (de)	2006-09-22	2007-09-20	Optimierung der behandlung philadelphia-positiver leukämie mit abl-tyrosinkinasehemmer imatinib

Country Status (24)

Country	Link
US (2)	US20090281113A1 (de)
EP (2)	EP2251042A3 (de)
JP (1)	JP5735742B2 (de)
KR (1)	KR20090065512A (de)
AT (1)	ATE495761T1 (de)
AU (1)	AU2007299764B2 (de)
BR (1)	BRPI0717099A2 (de)
CA (1)	CA2662977A1 (de)
CL (1)	CL2007002725A1 (de)
CY (1)	CY1111356T1 (de)
DE (1)	DE602007012122D1 (de)
DK (1)	DK2068938T3 (de)
HR (1)	HRP20110250T1 (de)
IL (1)	IL197296A (de)
MA (1)	MA30786B1 (de)
MX (1)	MX2009003082A (de)
NO (1)	NO20091490L (de)
NZ (1)	NZ575113A (de)
PL (1)	PL2068938T3 (de)
PT (1)	PT2068938E (de)
TN (1)	TN2009000094A1 (de)
TW (1)	TWI398251B (de)
WO (1)	WO2008036792A2 (de)
ZA (1)	ZA200901220B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2237783T3 (pl) *	2008-01-23	2015-04-30	Novartis Ag	Sposób optymalizacji leczenia chorób proliferacyjnych, w których pośredniczy receptor kinazy tyrozynowej kit, z użyciem imatynibu
US8697702B2 (en)	2008-12-01	2014-04-15	Novartis Ag	Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
US20110046919A1 (en) *	2009-03-02	2011-02-24	Juliesta Elaine Sylvester	Method for accurate measurement of enzyme activities
FR2943418A1 (fr) *	2009-03-17	2010-09-24	Centre Nat Rech Scient	Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications
EP3072964A1 (de) *	2013-11-22	2016-09-28	National Center For Child Health And Development	Neuartiges chimäres gen atf7ip-pdgfrb für akute lymphoblastische leukämie
US9683220B2 (en)	2015-07-07	2017-06-20	Codexis, Inc.	P450-BM3 variants with improved activity
IT201900008808A1 (it)	2019-06-13	2020-12-13	Univ Ca Foscari	Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma
CN114994213A (zh) *	2022-06-28	2022-09-02	北京赛诺浦生物技术有限公司	一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5521184A (en)	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es)	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP1169038B9 (de)	1999-04-15	2013-07-10	Bristol-Myers Squibb Company	Cyclische protein-tyrosinkinasehemmer
GB0202873D0 (en)	2002-02-07	2002-03-27	Novartis Ag	Organic compounds
JP2005522221A (ja) *	2002-04-17	2005-07-28	ノバルティスアクチエンゲゼルシャフト	チロシンキナーゼ阻害剤に対する患者応答性の予測方法
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
GB0222514D0 (en)	2002-09-27	2002-11-06	Novartis Ag	Organic compounds
RU2401265C2 (ru)	2004-06-10	2010-10-10	Айрм Ллк	Соединения и композиции в качестве ингибиторов протеинкиназы
GB0421525D0 (en)	2004-09-28	2004-10-27	Novartis Ag	Inhibitors of protein kineses
MY148074A (en)	2005-05-10	2013-02-28	Novartis Ag	Pharmaceutical compositions comprising imatinib and a release retardant

2007
- 2007-09-20 PT PT07842842T patent/PT2068938E/pt unknown
- 2007-09-20 US US12/442,126 patent/US20090281113A1/en not_active Abandoned
- 2007-09-20 DK DK07842842.2T patent/DK2068938T3/da active
- 2007-09-20 EP EP10171365A patent/EP2251042A3/de not_active Withdrawn
- 2007-09-20 BR BRPI0717099-8A patent/BRPI0717099A2/pt not_active IP Right Cessation
- 2007-09-20 CA CA002662977A patent/CA2662977A1/en not_active Abandoned
- 2007-09-20 AT AT07842842T patent/ATE495761T1/de active
- 2007-09-20 KR KR1020097005757A patent/KR20090065512A/ko not_active Ceased
- 2007-09-20 EP EP07842842A patent/EP2068938B1/de not_active Not-in-force
- 2007-09-20 JP JP2009529384A patent/JP5735742B2/ja not_active Expired - Fee Related
- 2007-09-20 HR HR20110250T patent/HRP20110250T1/hr unknown
- 2007-09-20 DE DE602007012122T patent/DE602007012122D1/de active Active
- 2007-09-20 MX MX2009003082A patent/MX2009003082A/es active IP Right Grant
- 2007-09-20 NZ NZ575113A patent/NZ575113A/en not_active IP Right Cessation
- 2007-09-20 PL PL07842842T patent/PL2068938T3/pl unknown
- 2007-09-20 AU AU2007299764A patent/AU2007299764B2/en not_active Ceased
- 2007-09-20 WO PCT/US2007/078978 patent/WO2008036792A2/en not_active Ceased
- 2007-09-21 TW TW096135633A patent/TWI398251B/zh not_active IP Right Cessation
- 2007-09-21 CL CL200702725A patent/CL2007002725A1/es unknown
2009
- 2009-02-20 ZA ZA2009/01220A patent/ZA200901220B/en unknown
- 2009-02-26 IL IL197296A patent/IL197296A/en not_active IP Right Cessation
- 2009-03-19 TN TN2009000094A patent/TN2009000094A1/fr unknown
- 2009-04-10 MA MA31775A patent/MA30786B1/fr unknown
- 2009-04-16 NO NO20091490A patent/NO20091490L/no not_active Application Discontinuation
2011
- 2011-03-23 CY CY20111100319T patent/CY1111356T1/el unknown
2016
- 2016-09-22 US US15/272,576 patent/US20170007605A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TN2009000094A1 (en)	2010-08-19
HK1133194A1 (en)	2010-03-19
EP2251042A3 (de)	2012-05-02
PL2068938T3 (pl)	2011-06-30
CY1111356T1 (el)	2015-08-05
US20170007605A1 (en)	2017-01-12
TWI398251B (zh)	2013-06-11
CA2662977A1 (en)	2008-03-27
DK2068938T3 (da)	2011-04-04
IL197296A (en)	2011-11-30
NZ575113A (en)	2012-03-30
WO2008036792A2 (en)	2008-03-27
HRP20110250T1 (hr)	2011-05-31
EP2068938B1 (de)	2011-01-19
CL2007002725A1 (es)	2008-05-16
EP2251042A2 (de)	2010-11-17
NO20091490L (no)	2009-06-15
WO2008036792A3 (en)	2008-11-13
KR20090065512A (ko)	2009-06-22
BRPI0717099A2 (pt)	2013-10-15
AU2007299764A1 (en)	2008-03-27
TW200822926A (en)	2008-06-01
US20090281113A1 (en)	2009-11-12
PT2068938E (pt)	2011-03-23
EP2068938A2 (de)	2009-06-17
MX2009003082A (es)	2009-04-01
DE602007012122D1 (de)	2011-03-03
MA30786B1 (fr)	2009-10-01
JP5735742B2 (ja)	2015-06-17
IL197296A0 (en)	2011-08-01
ZA200901220B (en)	2010-02-24
RU2009114856A (ru)	2010-10-27
AU2007299764B2 (en)	2011-10-13
JP2010504353A (ja)	2010-02-12

Similar Documents

Publication	Publication Date	Title
CY1111356T1 (el)	2015-08-05	Βελτιστοποιηση της θεραπειας της θετικης στο χρωμοσωμα της φιλαδελφειας λευχαιμιας με ιματινιμπη, εναν αναστολεα κινασης τυροσινης toy abl
Cappuzzo et al.	2003	Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
EA201190042A1 (ru)	2012-02-28	Имидазопиразиновые ингибиторы тирозинкиназы syk
HUP0302332A2 (hu)	2003-10-28	Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére
DK1509230T3 (da)	2007-05-14	Gefitinib ( IRESSA) til behandlingen af cancer
Hoyt et al.	2016	Sleep quality and depressive symptoms after prostate cancer: The mechanistic role of cortisol.
EA201892542A1 (ru)	2019-06-28	Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19
KR20220108201A (ko)	2022-08-02	수면 개선 방법
Scherer et al.	2009	Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents
ATE454465T1 (de)	2010-01-15	In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
Kokubun et al.	2007	Neurophysiological evaluation of trigeminal and facial nerves in patients with chronic inflammatory demyelinating polyneuropathy
Lundin et al.	2013	How active are patients with idiopathic normal pressure hydrocephalus and does activity improve after shunt surgery? A controlled actigraphic study
WO2010066891A3 (en)	2010-08-26	Method for predicting the response to treatment by tyrosine kinase inhibitors targeting the bcr-abl fusion protein in chronic myeloid leukaemia patients
RU2010101634A (ru)	2011-07-27	Способ оптимизации лечения хронического миелолейкоза с помощью ингибиторов трирозинкиназы abi
ATE402739T1 (de)	2008-08-15	Behandlung von entzündungen
EA201300410A1 (ru)	2014-01-30	Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2
RU2011122721A (ru)	2012-12-20	Способ оптимизации лечения хронического миелолейкоза ингибиторами тирозинказы abl
Büchner et al.	2004	Two years of experience using stimulation rates between 800 and 5000 pps with the clarion CII implant
ATE312612T1 (de)	2005-12-15	Methode zur optimierung der verwendung von 6- mercaptopurin in der behandlung von immun- vermittelten gastrointestinalen störungen
TW200507828A (en)	2005-03-01	Method for treatment of chemotherapy-induced diarrhea
EP2370078A1 (de)	2011-10-05	Verfahren zur optimierung der behandlung von philadelphia-positiver leukämie mit imatinib mesylat
Bonhof et al.	2021	Impact of peripheral neuropathy on sleep quality among colorectal cancer patients from diagnosis until 2-year follow-up: results from the PROFILES registry
WO2001045690A3 (en)	2002-07-25	Use of bvdu for inhibiting the growth of hyperproliferative cells
RU2483732C2 (ru)	2013-06-10	СПОСОБ ОПТИМИЗАЦИИ ЛЕЧЕНИЯ ЛЕЙКОЗА, ПОЛОЖИТЕЛЬНОГО ПО ФИЛАДЕЛЬФИЙСКОЙ ХРОМОСОМЕ, ИНГИБИТОРАМИ Ab1-ТИРОЗИНКИНАЗЫ
Laudanski	2016	Specific or Nonspecific? There Is Very Little Light at the End of the Tunnel

Legal Events

Date

Code

Title

Description

2011-08-15

UEP

Publication of translation of european patent specification

Ref document number: 2068938

Country of ref document: EP